Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Lixisenatide

MARKETED

GLP-1 receptor agonist (exendin-4-based)

3
graded findings
3
effect domains
Evidence spread
High evidence 2Moderate evidence 1Low evidence 0Very low evidence 0

Lixisenatide is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Lixisenatide MARKETED
Cardiovascular outcomes No change
High evidence

In T2D after a recent acute coronary syndrome, lixisenatide was non-inferior but NOT superior to placebo for the CV composite: a fully NEUTRAL CV outcome.

Pfeffer MA et al. (ELIXA), NEJM, 2015 Source
PopulationELIXA: N=6068; T2D with ACS within 180 days; double-blind placebo-controlled RCT; median 25 months.
Fundingindustry - Sanofi (disclosed in publication)
Scope limitsidentifier not fully verified
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Lixisenatide MARKETED
cns-neuropsychiatric Decrease
Moderate evidence

NEURODEGENERATION (Parkinson's) - the middle pole: in the LIXIPARK phase-2 trial in early Parkinson's, lixisenatide produced less motor-disability progression than...

Meissner WG, Remy P, Giordana C et al., N Engl J Med, 2024 (LIXIPARK) Source
Full findingNEURODEGENERATION (Parkinson's) - the middle pole: in the LIXIPARK phase-2 trial in early Parkinson's, lixisenatide produced less motor-disability progression than placebo at 12 months (~3-point MDS-UPDRS difference), but the effect attenuated after washout and came with substantial GI side effects.
PopulationLIXIPARK (NCT03439943): N=156 early PD (<3 years); double-blind RCT; daily s.c. lixisenatide, 12 months + 2-month washout.
Fundingacademic / non-commercial (LIXIPARK; French PHRC government programme; disclosed)
Scope limitssmall sample (N~156)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Lixisenatide MARKETED
Glycaemic control Decrease
High evidence

In the GetGoal phase 3 programme lixisenatide reduced HbA1c by approx 0.5-0.9%; in the ELIXA cardiovascular outcomes trial it was MACE-neutral vs placebo in T2D after...

Pfeffer MA et al., NEJM 2015 (ELIXA) Source
Full findingIn the GetGoal phase 3 programme lixisenatide reduced HbA1c by approx 0.5-0.9%; in the ELIXA cardiovascular outcomes trial it was MACE-neutral vs placebo in T2D after acute coronary syndrome.
PopulationGetGoal: ~5000 T2D across settings. ELIXA: 6068 T2D within 70 days of ACS, lixisenatide vs placebo, median ~2.1 years
Fundingindustry - Sanofi
Scope limitsMechanism: exendin-4-derived short-acting GLP-1 receptor agonist with pronounced gastric-emptying delay (strong postprandial lowering). Marketed Adlyxin (US)/Lyxumia (EU); also fixed-ratio with insulin glargine (Soliqua/Suliqua). First GLP-1 RA CV outcomes trial; CV-safe, no benefit. Later largely withdrawn commercially in some markets.
Comparatorsplacebo